MPM BioImpact LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001687078

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2023 · 32 positions · Total reported value $374.60M · Top-10 concentration 61.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 81.2% · 7 new · 21 cut · 11 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +31.4% · vs SPY +16.6% · Prev Value $1.29B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2023 13F filing, MPM BioImpact LLC disclosed 32 equity positions with a combined reported value of $374.60M. The filing implies a focused portfolio: its ten largest positions account for 61.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were CGEM ($69.22M), OLMA ($22.94M), GERN ($22.71M). By sector, the heaviest allocations are Health Care 69.3%, Materials 1.1%.

Versus the prior quarter, MPM BioImpact LLC opened 7 new positions, trimmed 21 and fully exited 11, a turnover rate of 81.2% of positions.

The largest new positions opened in Q3 2023 were CGEM ($69.22M), OLMA ($22.94M), GERN ($22.71M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • CGEM CULLINAN THERAPEUTICS INC · $69.22M
  • OLMA OLEMA PHARMACEUTICALS INC · $22.94M
  • GERN GERON CORP · $22.71M
  • RPTX REPARE THERAPEUTICS INC · $19.81M
  • ITOS ITEOS THERAPEUTICS INC · $19.12M
  • NTLA INTELLIA THERAPEUTICS INC · $17.22M
  • MLTX MOONLAKE IMMUNOTHERAPEUTICS · $16.77M
  • IOVA IOVANCE BIOTHERAPEUTICS · $14.96M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest MPM BioImpact LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

MPM BioImpact LLC, based in Boston, MA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 37 positions worth $1.64B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-106989 (status: Approved), registered 2016-01-04
  • Regulatory AUM (Form ADV): $3.56B as of 2026-04-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 14 private funds, of which 3 hedge funds

Portfolio Structure

  • 37 positions · $1.64B reported value (Q2 2026)
  • Top 10 holdings = 55.3% of reported value
  • Largest position: CGEM (CULLINAN THERAPEUTICS INC) at 10.8%
  • Average position size: $44.32M

Sector Tilt

  • Health Care 98.7%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 7 new, 7 added, 21 reduced, 11 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 69.3%
Materials 1.1%
Other 29.6%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 7.65M $69.22M 18.48%
18.48%
New
2 1.86M $22.94M 6.12%
6.12%
New
3 10.71M $22.71M 6.06%
6.06%
New
4 1.64M $19.81M 5.29%
5.29%
New
5 1.75M $19.12M 5.10%
5.10%
New
6 544.64K $17.22M 4.60%
4.60%
New
7 294.19K $16.77M 4.48%
4.48%
New
8 3.29M $14.96M 3.99%
3.99%
New
9 479.05K $14.25M 3.80%
3.80%
New
10 527.46K $13.32M 3.56%
3.56%
New
11 230.76K $11.63M 3.11%
3.11%
New
12 857.94K $11.38M 3.04%
3.04%
New
13 1.35M $11.37M 3.04%
3.04%
New
14 656.72K $10.81M 2.89%
2.89%
New
15 610.77K $9.11M 2.43%
2.43%
New
16 53.21K $9.00M 2.40%
2.40%
New
17 716.14K $8.71M 2.33%
2.33%
New
18 273.41K $7.57M 2.02%
2.02%
New
19 3.99M $7.42M 1.98%
1.98%
New
20 664.22K $6.84M 1.83%
1.83%
New
21 93.59K $6.54M 1.75%
1.75%
New
22 40.86K $5.97M 1.59%
1.59%
New
23 577.96K $5.57M 1.49%
1.49%
New
24 2.39M $5.11M 1.36%
1.36%
New
25 552.85K $4.94M 1.32%
1.32%
New
26 200.00K $4.58M 1.22%
1.22%
New
27 5.10M $3.97M 1.06%
1.06%
New
28 255.32K $3.92M 1.05%
1.05%
New
29 347.33K $3.60M 0.96%
0.96%
New
30 325.00K $3.60M 0.96%
0.96%
New
31 326.92K $1.37M 0.37%
0.37%
New
32 319.67K $1.29M 0.34%
0.34%
New

FAQ

What did MPM BioImpact LLC buy in 2023-Q3?

In its 2023-Q3 13F filing, MPM BioImpact LLC reported 32 equity positions worth $374.60M in aggregate; its largest disclosed positions were CGEM ($69.22M), OLMA ($22.94M), GERN ($22.71M).

How large is MPM BioImpact LLC's portfolio?

MPM BioImpact LLC reported $374.60M of long equity holdings across 32 positions as of 2023-Q3. Top-10 holdings account for 61.5% of reported value.

What is MPM BioImpact LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/mpm-bioimpact/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →